Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
Lilly's Mounjaro to cost 2,200 Danish crowns per month
Wegovy's price ranges from 1,313 to 2,353 crowns per month
Denmark's public health system does not reimburse weight-loss drugs
COPENHAGEN, Oct 24 (Reuters) -Lilly LLY.N will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals group Novo Nordisk NOVOb.CO.
The two drugmakers are the first-to-market with highly effective obesity treatments, a booming business that could be worth $150 billion in annual global sales by the early 2030s, according to some analysts.
In Denmark, Lilly is up against Novo whose drug Wegovy has seen a global whirlwind success that made the Danish group Europe's most valuable company and boosted the national economy.
Both Mounjaro and Wegovy are cleared for weight loss in combination with a reduced-calorie diet and increased physical activity, and come with added health benefits alleviating many problems linked to excess weight.
The price would be roughly 2,200 Danish crowns ($318.5) per month, a Lilly spokesperson told Reuters.
The monthly price of Wegovy varies from 1,313 crowns for a starter dose, to 2,353 crowns for the maximum maintenance dose, according to the website of the Danish medicines agency.
The number of users of Wegovy in Denmark increased from around 60,000 in January to 90,000 in August, which corresponded with 713,950 injection pens in the first eight months of this year, data from the Danish Health Data Authority showed.
In Denmark, a country of roughly 6 million people, around 19% of the population has a body mass index (BMI) of 30 or above.
The public health care system does not generally reimburse weight-loss drugs and the country's largest private health insurer, which covers roughly half the population, stopped paying for such drugs in 2023 due to high demand.
Mounjaro was launched in Sweden and Finland last week and will soon be launched in Norway, the spokesperson said. Elsewhere in Europe, the drug has also been introduced in the UK, Poland, Spain, Switzerland and Germany.
($1 = 6.9076 Danish crowns)
Reporting by Stine Jacobsen and Louise Breusch Rasmussen
Editing by Tomasz Janowski
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
